Cellectis CEO Selected as Speaker for 2017 Milken Institute Global Conference
April 27 2017 - 4:30PM
Business Wire
Dr. André Choulika to Serve as Panelist for
“Humankind vs. Cancer: The Scorecard”
Regulatory News:
Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS; Nasdaq:
CLLS), a biopharmaceutical company focused on developing
immunotherapies based on gene edited CAR T-cells (UCART), today
announced that the Company’s founder, Chairman and CEO, Dr. André
Choulika, has been selected as a speaker for the 2017 Milken
Institute Global Conference. Dr. Choulika will participate as a
panelist for a session titled, “Humankind vs. Cancer: The
Scorecard” on Wednesday, May 3, 2017, at 10 a.m. local time.
This panel will focus on both the opportunities and challenges
that come with fighting cancer using new targeted therapies and
breakthrough immuno-oncology drugs, addressing questions such as:
Why do many breakthrough treatments work for some patients but not
others? What are some of the risks that are associated with
emerging treatments? Can patients, governments and insurers
continue to meet the rising costs of cancer treatment? Will the
changes in administration impact commitments that are made through
the Cancer MoonShot and 21st Century Cures Act?
Dr. Choulika’s selection as a speaker was based on his
contribution to and impact on the global healthcare and life
sciences industries through Cellectis’ development and therapeutic
application of allogeneic, off-the-shelf CAR T-cell immunotherapies
that target cancer. With this process, T-cells from healthy donors
are genetically edited with Cellectis’ proprietary TALEN®
technology to seek and destroy cancer cells.
The 20th Annual Milken Institute Global Conference will take
place on Sunday, April 30, to Wednesday, May 3, 2017, in Los
Angeles, California.
About Cellectis
Cellectis is a biopharmaceutical company focused on developing
immunotherapies based on gene-edited CAR T-cells (UCART). The
company’s mission is to develop a new generation of cancer
therapies based on engineered T-cells. Cellectis capitalizes on its
17 years of expertise in genome engineering - based on its flagship
TALEN® products and meganucleases as well as its pioneering
electroporation PulseAgile technology - to create a new generation
of immunotherapies. CAR technologies are designed to target surface
antigens expressed on cells. Using its life-science-focused,
pioneering genome-engineering technologies, Cellectis’ goal is to
create innovative products in multiple fields and with various
target markets.
Cellectis is listed on the Nasdaq market (ticker: CLLS) and on
the NYSE Alternext market (ticker: ALCLS). To find out more about
us, visit our website: www.cellectis.com
Talking about gene editing? We do it. TALEN® is a registered
trademark owned by the Cellectis Group
Disclaimer
This press release and the information contained herein do not
constitute an offer to sell or subscribe, or a solicitation of an
offer to buy or subscribe, for shares in Cellectis in any country.
This press release contains forward-looking statements that relate
to the Company’s objectives based on the current expectations and
assumptions of the Company’s management only and involve risk and
uncertainties that could cause the Company to fail to achieve the
objectives expressed by the forward-looking statements above.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170427006670/en/
CellectisMedia:Jennifer Moore, 917-580-1088VP of
Communicationsmedia@cellectis.comorCaitlin Kasunich,
212-896-1241KCSA Strategic
Communicationsckasunich@kcsa.comIR:Simon Harnest,
646-385-9008VP of Corporate Strategy and
Financesimon.harnest@cellectis.com
Cellectis (NASDAQ:CLLS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cellectis (NASDAQ:CLLS)
Historical Stock Chart
From Apr 2023 to Apr 2024